PET scans of abdominal malignancy.
Positron emission tomography (PET) with fluorine-18-2-d-deoxyglucose (FDG) currently is being integrated into clinical oncology because it provides unique functional information that can be applied to the management of cancer. In particular, it is useful for assessing tumor activity and growth, evaluating efficacy of therapy, and detecting tumor recurrence. Studies have demonstrated the value of whole-body PET-FDG imaging when staging and managing abdominal malignancy.
Blahd
W H
WH
Nuclear Medicine Service, West Los Angeles Veterans Affairs Medical Center, 11301 Wilshire Boulevard, Los Angeles, California 90073, USA.
Brown
C V
CV
Khonsary
S A
SA
Farahi
J B
JB
Quinones
N
N
Ribe
J Y
JY
Coyle
J J
JJ
Glass
E C
EC
Mandelkern
M A
MA
D000008:Abdominal Neoplasms / Q000000981:diagnostic imaging*; D003110:Colonic Neoplasms / Q000000981:diagnostic imaging; D003847:Deoxyglucose / Q000031:analogs & derivatives; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D012004:Rectal Neoplasms / Q000000981:diagnostic imaging; D014055:Tomography, Emission-Computed / Q000295:instrumentation* / Q000379:methods
D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose